| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 15 | 2025 | 835 | 3.090 |
Why?
|
| Hypertension | 27 | 2021 | 1301 | 2.260 |
Why?
|
| Antihypertensive Agents | 13 | 2021 | 399 | 1.630 |
Why?
|
| Primary Health Care | 15 | 2017 | 776 | 1.560 |
Why?
|
| Cognition | 9 | 2025 | 784 | 1.110 |
Why?
|
| Cognition Disorders | 6 | 2019 | 542 | 1.100 |
Why?
|
| Cognitive Reserve | 1 | 2025 | 5 | 0.960 |
Why?
|
| Cognitive Dysfunction | 6 | 2025 | 285 | 0.940 |
Why?
|
| tau Proteins | 2 | 2025 | 236 | 0.840 |
Why?
|
| Neuropsychological Tests | 8 | 2024 | 951 | 0.740 |
Why?
|
| Computer Communication Networks | 1 | 2022 | 16 | 0.730 |
Why?
|
| International Cooperation | 1 | 2022 | 157 | 0.690 |
Why?
|
| Blood Pressure | 8 | 2021 | 1312 | 0.680 |
Why?
|
| Dementia | 5 | 2025 | 416 | 0.640 |
Why?
|
| Medication Adherence | 4 | 2021 | 330 | 0.630 |
Why?
|
| Aged | 35 | 2025 | 20344 | 0.590 |
Why?
|
| Disease Progression | 4 | 2021 | 2109 | 0.580 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 1184 | 0.580 |
Why?
|
| Caregivers | 1 | 2023 | 554 | 0.550 |
Why?
|
| Brain | 3 | 2025 | 3038 | 0.540 |
Why?
|
| Patient Compliance | 5 | 2014 | 458 | 0.470 |
Why?
|
| Drug Resistance | 2 | 2014 | 246 | 0.440 |
Why?
|
| Vestibular Function Tests | 1 | 2014 | 34 | 0.430 |
Why?
|
| Cohort Studies | 7 | 2025 | 4954 | 0.430 |
Why?
|
| Office Visits | 1 | 2014 | 78 | 0.420 |
Why?
|
| Middle Aged | 42 | 2025 | 27697 | 0.420 |
Why?
|
| Community Networks | 1 | 2013 | 30 | 0.410 |
Why?
|
| Vestibular Diseases | 1 | 2014 | 65 | 0.400 |
Why?
|
| Humans | 75 | 2025 | 126753 | 0.400 |
Why?
|
| Patient Education as Topic | 4 | 2016 | 452 | 0.400 |
Why?
|
| Cyclobutanes | 1 | 2013 | 7 | 0.400 |
Why?
|
| Mental Recall | 1 | 2014 | 137 | 0.400 |
Why?
|
| Male | 56 | 2025 | 62543 | 0.390 |
Why?
|
| Appetite Depressants | 1 | 2013 | 23 | 0.390 |
Why?
|
| Health Services Research | 2 | 2013 | 175 | 0.390 |
Why?
|
| Ceramides | 1 | 2012 | 46 | 0.370 |
Why?
|
| Female | 54 | 2025 | 68330 | 0.370 |
Why?
|
| Life Style | 6 | 2025 | 433 | 0.360 |
Why?
|
| Delivery of Health Care | 3 | 2016 | 667 | 0.350 |
Why?
|
| Weight Loss | 2 | 2013 | 503 | 0.350 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 456 | 0.330 |
Why?
|
| Aged, 80 and over | 15 | 2024 | 6668 | 0.320 |
Why?
|
| Vitamin E | 1 | 2009 | 62 | 0.310 |
Why?
|
| Vestibular Evoked Myogenic Potentials | 2 | 2022 | 11 | 0.300 |
Why?
|
| Amyloid beta-Peptides | 3 | 2025 | 225 | 0.300 |
Why?
|
| Electronic Health Records | 3 | 2016 | 781 | 0.300 |
Why?
|
| Elder Abuse | 4 | 2002 | 23 | 0.290 |
Why?
|
| Education | 2 | 2006 | 107 | 0.290 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 290 | 0.280 |
Why?
|
| Texas | 16 | 2016 | 3551 | 0.280 |
Why?
|
| Insulin | 2 | 2013 | 1128 | 0.280 |
Why?
|
| Vaccination | 4 | 2017 | 1004 | 0.280 |
Why?
|
| Adult | 32 | 2018 | 30410 | 0.280 |
Why?
|
| Antioxidants | 1 | 2009 | 321 | 0.270 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 2036 | 0.260 |
Why?
|
| Positron-Emission Tomography | 2 | 2025 | 291 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2006 | 1352 | 0.250 |
Why?
|
| Intelligence Tests | 1 | 2006 | 59 | 0.250 |
Why?
|
| Immunization Programs | 2 | 2017 | 66 | 0.250 |
Why?
|
| Educational Status | 2 | 2025 | 274 | 0.250 |
Why?
|
| Physicians | 2 | 2011 | 620 | 0.250 |
Why?
|
| Intelligence | 1 | 2006 | 91 | 0.240 |
Why?
|
| Entorhinal Cortex | 1 | 2025 | 27 | 0.240 |
Why?
|
| Healthy Aging | 1 | 2025 | 12 | 0.230 |
Why?
|
| Patient Participation | 1 | 2007 | 231 | 0.220 |
Why?
|
| Obesity | 4 | 2013 | 2332 | 0.220 |
Why?
|
| United States | 12 | 2025 | 11310 | 0.220 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 292 | 0.220 |
Why?
|
| Risk Reduction Behavior | 1 | 2025 | 145 | 0.210 |
Why?
|
| Biomarkers | 5 | 2024 | 3222 | 0.210 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 694 | 0.200 |
Why?
|
| Markov Chains | 1 | 2023 | 94 | 0.200 |
Why?
|
| Health Promotion | 2 | 2016 | 400 | 0.200 |
Why?
|
| Chest Pain | 1 | 2004 | 124 | 0.200 |
Why?
|
| Mood Disorders | 1 | 2004 | 124 | 0.190 |
Why?
|
| Exercise Test | 1 | 2004 | 243 | 0.190 |
Why?
|
| Cohort Effect | 2 | 2019 | 4 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2011 | 1193 | 0.190 |
Why?
|
| Risk Factors | 16 | 2025 | 10555 | 0.190 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 98 | 0.180 |
Why?
|
| Self Efficacy | 2 | 2013 | 198 | 0.180 |
Why?
|
| Physician's Role | 1 | 2003 | 159 | 0.170 |
Why?
|
| Blood Pressure Determination | 4 | 2011 | 107 | 0.170 |
Why?
|
| Mortality | 1 | 2003 | 254 | 0.170 |
Why?
|
| Prostatic Neoplasms | 2 | 2007 | 1396 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 1259 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1428 | 0.170 |
Why?
|
| Health Services for the Aged | 1 | 2001 | 34 | 0.170 |
Why?
|
| Influenza, Human | 2 | 2017 | 674 | 0.170 |
Why?
|
| Cholinergic Neurons | 1 | 2020 | 20 | 0.170 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2020 | 54 | 0.160 |
Why?
|
| Regression Analysis | 5 | 2016 | 759 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 181 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 2225 | 0.150 |
Why?
|
| Health Surveys | 3 | 2013 | 248 | 0.150 |
Why?
|
| Health Behavior | 3 | 2012 | 385 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 5114 | 0.140 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 3 | 2013 | 49 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 429 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 679 | 0.140 |
Why?
|
| Mass Screening | 3 | 2014 | 802 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 306 | 0.140 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1999 | 163 | 0.140 |
Why?
|
| Anxiety | 1 | 2023 | 964 | 0.130 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2016 | 3 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2000 | 613 | 0.130 |
Why?
|
| Exercise | 5 | 2025 | 839 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 750 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 2 | 2007 | 235 | 0.120 |
Why?
|
| Linear Models | 3 | 2011 | 681 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 849 | 0.120 |
Why?
|
| Telephone | 1 | 1996 | 112 | 0.120 |
Why?
|
| Immunization | 1 | 2017 | 300 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 110 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2014 | 1194 | 0.120 |
Why?
|
| Logistic Models | 5 | 2004 | 1779 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 370 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 174 | 0.110 |
Why?
|
| New York | 1 | 2015 | 69 | 0.110 |
Why?
|
| Dizziness | 1 | 2014 | 26 | 0.110 |
Why?
|
| Education, Medical | 2 | 2003 | 281 | 0.110 |
Why?
|
| Minority Groups | 3 | 1993 | 250 | 0.110 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 402 | 0.100 |
Why?
|
| Prevalence | 6 | 2004 | 2591 | 0.100 |
Why?
|
| White Coat Hypertension | 1 | 2013 | 10 | 0.100 |
Why?
|
| Diabetes Mellitus | 3 | 2013 | 873 | 0.100 |
Why?
|
| Physical Examination | 1 | 2014 | 160 | 0.100 |
Why?
|
| Education, Premedical | 2 | 1991 | 2 | 0.100 |
Why?
|
| Alcoholics Anonymous | 1 | 2013 | 3 | 0.100 |
Why?
|
| Temperance | 1 | 2013 | 15 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2013 | 14 | 0.100 |
Why?
|
| Health Literacy | 1 | 2014 | 72 | 0.100 |
Why?
|
| Postural Balance | 1 | 2014 | 129 | 0.100 |
Why?
|
| Religion and Medicine | 1 | 2013 | 26 | 0.100 |
Why?
|
| Biostatistics | 1 | 2012 | 12 | 0.100 |
Why?
|
| Motivation | 3 | 2016 | 322 | 0.100 |
Why?
|
| Smoking Cessation | 2 | 2012 | 183 | 0.100 |
Why?
|
| Spirituality | 1 | 2013 | 48 | 0.100 |
Why?
|
| Patient Selection | 1 | 1996 | 711 | 0.100 |
Why?
|
| Systole | 3 | 2011 | 193 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 221 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12546 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 481 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2014 | 557 | 0.090 |
Why?
|
| Internal Medicine | 3 | 2016 | 123 | 0.090 |
Why?
|
| Young Adult | 3 | 2018 | 9665 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1999 | 824 | 0.090 |
Why?
|
| Epilepsy | 1 | 2018 | 844 | 0.090 |
Why?
|
| Sphingomyelins | 1 | 2011 | 15 | 0.090 |
Why?
|
| Uncertainty | 1 | 2011 | 94 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2017 | 684 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2011 | 950 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 223 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 534 | 0.080 |
Why?
|
| Alcoholism | 1 | 2013 | 242 | 0.080 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 184 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2014 | 659 | 0.080 |
Why?
|
| Emigration and Immigration | 2 | 2001 | 81 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 3662 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2007 | 880 | 0.080 |
Why?
|
| Surveys and Questionnaires | 7 | 2018 | 3907 | 0.080 |
Why?
|
| Body Mass Index | 5 | 2007 | 1654 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2009 | 1495 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 482 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 785 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2009 | 466 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2022 | 17005 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2013 | 3314 | 0.060 |
Why?
|
| Survival | 1 | 2006 | 14 | 0.060 |
Why?
|
| Pennsylvania | 2 | 2016 | 57 | 0.060 |
Why?
|
| Community Health Centers | 3 | 2003 | 37 | 0.060 |
Why?
|
| Relief Work | 1 | 2006 | 31 | 0.060 |
Why?
|
| Diuretics | 2 | 2013 | 153 | 0.060 |
Why?
|
| Anthropometry | 2 | 2004 | 190 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2021 | 6214 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3695 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2003 | 1364 | 0.060 |
Why?
|
| Social Participation | 1 | 2025 | 12 | 0.060 |
Why?
|
| Geriatrics | 2 | 2006 | 62 | 0.060 |
Why?
|
| Counseling | 1 | 2007 | 233 | 0.060 |
Why?
|
| Disasters | 1 | 2006 | 100 | 0.060 |
Why?
|
| Motor Activity | 2 | 2007 | 504 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 233 | 0.060 |
Why?
|
| Apolipoprotein E4 | 1 | 2024 | 47 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 557 | 0.050 |
Why?
|
| GTP-Binding Proteins | 2 | 2002 | 160 | 0.050 |
Why?
|
| Reaction Time | 1 | 2004 | 156 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 110 | 0.050 |
Why?
|
| Visual Perception | 1 | 2004 | 124 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2004 | 172 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2003 | 73 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2004 | 140 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2006 | 822 | 0.050 |
Why?
|
| Specialization | 1 | 2003 | 74 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2004 | 873 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 77 | 0.050 |
Why?
|
| Medicine | 1 | 2003 | 100 | 0.050 |
Why?
|
| Blood Glucose | 3 | 2001 | 1082 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2002 | 3262 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2009 | 3586 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2006 | 409 | 0.050 |
Why?
|
| Family Practice | 2 | 2016 | 86 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 338 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2024 | 359 | 0.040 |
Why?
|
| Program Evaluation | 3 | 2016 | 437 | 0.040 |
Why?
|
| Prejudice | 1 | 2001 | 38 | 0.040 |
Why?
|
| Geriatric Assessment | 2 | 2000 | 182 | 0.040 |
Why?
|
| Learning | 1 | 2004 | 357 | 0.040 |
Why?
|
| Awareness | 1 | 2001 | 78 | 0.040 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 345 | 0.040 |
Why?
|
| Lipids | 1 | 2004 | 550 | 0.040 |
Why?
|
| Sampling Studies | 2 | 2001 | 75 | 0.040 |
Why?
|
| Syndrome | 1 | 2004 | 1137 | 0.040 |
Why?
|
| Incidence | 2 | 2001 | 3251 | 0.040 |
Why?
|
| Cause of Death | 1 | 2003 | 484 | 0.040 |
Why?
|
| Acute Disease | 1 | 2004 | 1135 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2001 | 134 | 0.040 |
Why?
|
| Genotype | 2 | 2020 | 2595 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 4304 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1374 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2001 | 116 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 146 | 0.040 |
Why?
|
| Cholinergic Antagonists | 1 | 2020 | 47 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2001 | 293 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 412 | 0.040 |
Why?
|
| Glycogen | 1 | 1999 | 50 | 0.040 |
Why?
|
| American Heart Association | 1 | 2021 | 307 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 1137 | 0.040 |
Why?
|
| Smoking | 1 | 2004 | 901 | 0.040 |
Why?
|
| Postprandial Period | 1 | 1999 | 85 | 0.040 |
Why?
|
| Social Work | 1 | 1999 | 20 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2000 | 210 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2000 | 214 | 0.040 |
Why?
|
| Urban Population | 2 | 1998 | 236 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2020 | 436 | 0.040 |
Why?
|
| Hyperglycemia | 2 | 1999 | 225 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 737 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 481 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 208 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2020 | 320 | 0.040 |
Why?
|
| Triglycerides | 1 | 2001 | 596 | 0.040 |
Why?
|
| Cholesterol | 1 | 2001 | 535 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2012 | 422 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2003 | 658 | 0.030 |
Why?
|
| Social Support | 2 | 2012 | 369 | 0.030 |
Why?
|
| Hippocampus | 1 | 2022 | 777 | 0.030 |
Why?
|
| Age of Onset | 2 | 2011 | 609 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 1996 | 46 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 82 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 237 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1193 | 0.030 |
Why?
|
| Alleles | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Random Allocation | 1 | 1996 | 415 | 0.030 |
Why?
|
| Urban Health | 2 | 2012 | 74 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2560 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 1166 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 1996 | 231 | 0.030 |
Why?
|
| Glucose | 1 | 1999 | 839 | 0.030 |
Why?
|
| Age Factors | 1 | 2001 | 2789 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1999 | 550 | 0.030 |
Why?
|
| Foot Diseases | 1 | 1993 | 21 | 0.030 |
Why?
|
| Protestantism | 1 | 2013 | 3 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 109 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2003 | 1195 | 0.020 |
Why?
|
| Poverty | 2 | 2012 | 431 | 0.020 |
Why?
|
| Sex Factors | 2 | 2000 | 1309 | 0.020 |
Why?
|
| Lisinopril | 1 | 2012 | 23 | 0.020 |
Why?
|
| Amlodipine | 1 | 2012 | 21 | 0.020 |
Why?
|
| Chlorthalidone | 1 | 2012 | 24 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2012 | 51 | 0.020 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2012 | 12 | 0.020 |
Why?
|
| Eye Diseases | 1 | 1993 | 97 | 0.020 |
Why?
|
| College Admission Test | 1 | 1991 | 6 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2012 | 95 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 219 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1992 | 241 | 0.020 |
Why?
|
| Korea | 1 | 2011 | 33 | 0.020 |
Why?
|
| Diastole | 1 | 2011 | 172 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 237 | 0.020 |
Why?
|
| Depression | 1 | 2000 | 1293 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 408 | 0.020 |
Why?
|
| Africa | 2 | 2001 | 134 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1595 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1992 | 396 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2012 | 640 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1222 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2007 | 43 | 0.020 |
Why?
|
| Sodium, Dietary | 1 | 2007 | 29 | 0.020 |
Why?
|
| Cotinine | 1 | 2007 | 23 | 0.020 |
Why?
|
| Group Processes | 1 | 2007 | 47 | 0.020 |
Why?
|
| Health Facility Environment | 1 | 2006 | 8 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2007 | 88 | 0.020 |
Why?
|
| Public Health Practice | 1 | 2006 | 19 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 275 | 0.020 |
Why?
|
| Focus Groups | 1 | 2007 | 215 | 0.020 |
Why?
|
| Triage | 1 | 2006 | 151 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 980 | 0.010 |
Why?
|
| Radiology | 1 | 2006 | 119 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 12771 | 0.010 |
Why?
|
| Mental Health Services | 1 | 2006 | 259 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 107 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 970 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 14347 | 0.010 |
Why?
|
| Adolescent | 2 | 2018 | 20002 | 0.010 |
Why?
|
| Angiotensinogen | 1 | 2001 | 21 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2007 | 706 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 53 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1984 | 329 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 2101 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 325 | 0.010 |
Why?
|
| Students, Medical | 1 | 1984 | 337 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 261 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2000 | 122 | 0.010 |
Why?
|
| Heart Failure | 1 | 2012 | 2289 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 2975 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 1999 | 229 | 0.010 |
Why?
|
| Gluconeogenesis | 1 | 1999 | 93 | 0.010 |
Why?
|
| Mandatory Reporting | 1 | 1999 | 17 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1999 | 142 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1999 | 199 | 0.010 |
Why?
|
| Mexican Americans | 1 | 1999 | 163 | 0.010 |
Why?
|
| Child | 1 | 2018 | 25101 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 1090 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 1656 | 0.010 |
Why?
|
| Pediatrics | 1 | 2006 | 1202 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2000 | 1207 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1999 | 761 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 683 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2001 | 1056 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 6134 | 0.010 |
Why?
|
| Cost Savings | 1 | 1993 | 78 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1993 | 93 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1993 | 130 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1993 | 194 | 0.010 |
Why?
|
| Health Education | 1 | 1993 | 222 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 2883 | 0.000 |
Why?
|